Intensity Therapeutics
INTS
2 hedge funds and large institutions have $170K invested in Intensity Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$169K |
| 2 |
GWS
Glassman Wealth Services
Vienna,
Virginia
|
+$1.19K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Walleye Capital
New York
| $169K | +$169K | +1,135 | New |
|
|
GWS
2
Glassman Wealth Services
Vienna,
Virginia
| $1.19K | +$1.19K | +8 | New |
|
INTS Hedge Fund Activity: Q2 2023 in Review
2 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q2 2023, worth a combined $170K.
Buyers outnumbered sellers: 2 funds opened new INTS positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $169K.
- 2 institutional investors held Intensity Therapeutics (INTS) as of Q2 2023, up from 0 in Q1 2023.
- Funds reported $170K of Intensity Therapeutics stock for Q2 2023.
- 2 funds opened new Intensity Therapeutics positions in Q2 2023 and 0 closed out, a net change of +2 holders.
- The largest Intensity Therapeutics buyer in Q2 2023 was Walleye Capital, an estimated $169K added.
Based on aggregated 13F filings for Q2 2023.